布鲁克推出领先的maXis II Q-TOF用于生命科学研究

Bruker Corporation. (11/3/14). "Press Release: Bruker Announces Industry Leading Quadrupole Time-of-Flight Mass Spectrometry for Life Sciene Research Analysis". Washington, DC.

Bruker Corporation (NASDAQ: BRKR) announced today, the evolution of their maXis™ line of ultrahigh-resolution quadrupole time-of-flight (UHR-qTOF) mass spectrometers, bringing industry-leading resolution and mass accuracy to the liquid chromatography, time-of-flight MS market space. The system, announced at IBC’s 18th annual Well Characterized Biologicals Conference, is designed to deliver outstanding resolution and mass accuracy which allows for unambiguous identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies for example. In addition, this level of performance also provides scientists confident detection and identification of modifications hard to detect at the protein level, such as deamidation.

"The maXis II system delivers the fastest time-to-success for life science researchers and across a broad range of applications from the in-depth identification and characterization of biopharmaceuticals and small molecule pharmaceuticals, to bottom-up proteomics and proteoform screening.” said Dr. Bob Galvin, Vice President of Bruker’s Biopharmaceutical Business Unit. “Additionally, the system is well suited to research in the metabolomics, food safety, and forensic and toxicology screening markets as well."


The maXis II™ – UHR-qTOF Mass Spectrometer

The new maXis II system is the latest flagship instrument in Bruker’s unique TOF mass spectrometry product line, allowing the simultaneous analysis of small molecules and megadalton proteins on one analytical platform.

The system delivers:

> Industry-leading (>80,000) Full-Sensitivity Resolution (FSR) at UPLC acquisition speeds thus enabling Bruker’s unique and industry acknowledged True Isotopic Pattern spectral acquisition. This allows for the identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies or, when linked to Smart Formula 3D provides unambiguous elemental formula determination for the pharmaceutical and related industries

产业领先的全扫描分辨率（FSR）：> 80,000，在UPLC的采集速度下，并具有布鲁克独有的、业界认可的真正同位素模式谱图采集。对于单克隆抗体的不管是轻链还是重链峰，都可鉴定其单同位素质谱峰；当连接于Smart Formula 3D 时，可给出不混淆的元素化学式鉴定结论，用于制药和相关产业。

> A High Mass Option (HMO) yielding native spray MS capabilities provides enhanced analytical performance levels, particularly suited for biopharmaceutical and pharmaceutical challenges, like the analysis of megadalton protein complexes and determination of antibody drug conjugates (ADCs)

高质量选项（HMO）产生天然的MS能力，增强分析性能，特别适用于生物制药和制药领域面临的挑战，比如分析megadalton蛋白复合物时，可测定抗体药的连接物（ADCs）

> The Electron Transfer Dissociation (ETD) option provides a powerful additional MS/MS fragmentation technique for the sequence analysis of intact proteins including monoclonal antibody subunits. The ETD MS/MS fragmentation technique is complimentary to collision induced dissociation (CID) MS/MS, yielding greater sequence coverage for proteins and providing additional capabilities to the new system
电子转移解离（ETD）选项，进行强大的另一种MS/MS碎裂，用于测序包括单克隆抗体亚单元的天然蛋白。  ETD MS/MS 碎裂技术是CID MS/MS技术的补充，产生蛋白更多的序列覆盖，为新系统增加性能。

Ordering Information

The maXis II mass spectrometer is available immediately. Please contact your local Bruker Sales Representative for a quote.


About Bruker Corporation

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com.


Media Contact:

Tony Lewtas
Bruker Corporation
T: +1 978 663 3660 ext.1212
E: tony.lewtas@bruker.com

Investor Contact:
Joshua Young
Vice President of Investor Relations, Bruker Corporation
T: +1 978 663 3660 ext.1479
E: joshua.young@bruker.com